Publications by authors named "D Meerkin"
Article Synopsis
- Haemodynamic monitoring with implantable pressure sensors lowers heart failure hospitalizations and empowers patients to manage their treatment, potentially enhancing adherence and reducing healthcare provider workloads.
- The VECTOR-HF I and IIa studies evaluate a patient self-management approach for heart failure, showing no serious complications and high adherence (91.4%) over a year, with significant reductions in hospitalizations and improvements in physical function and quality of life.
- Interim results indicate that patient self-management using left atrial pressure monitoring is safe, feasible, and may lead to better outcomes for heart failure patients.
Aims: In heart failure (HF), implantable haemodynamic monitoring devices have been shown to optimize therapy, anticipating clinical decompensation and preventing hospitalization. Direct left-sided haemodynamic sensors offer theoretical benefits beyond pulmonary artery pressure monitoring systems. We evaluated the safety, usability, and performance of a novel left atrial pressure (LAP) monitoring system in HF patients.
View Article and Find Full Text PDFObjective: Patients with heart failure (HF) are at an increased risk of hospital admissions. The aim of this report is to describe the feasibility, safety and accuracy of a novel wireless left atrial pressure (LAP) monitoring system in patients with HF.
Methods: The V-LAP Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heart Failure (VECTOR-HF) study is a prospective, multicenter, single-arm, open-label, first-in human clinical trial to assess the safety, performance and usability of the V-LAP system (Vectorious Medical Technologies) in patients with New York Heart Association class III HF.